F Scilla, G Gioco, L Ferrero, R Castagnola, A Zafarone, L Cimino, M Tranfa, C Rupe, C Lajolo
Background: Oral lichen planus (OLP) is a chronic immune-mediated disorder with malignant potential. However, its real-world clinical course remains incompletely characterized. This study aimed to describe the natural clinical-histopathological trajectory of OLP in a single tertiary centre and to identify factors associated with dysplasia and malignant transformation over time.
Methods: We conducted a single-centre retrospective cohort study including patients diagnosed with OLP and followed between 2007 and 2024 at the Oral Medicine Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS. Demographic, clinical (red vs. white phenotype and lesion distribution), microbiological (Candida spp.), therapeutic, and histopathological variables were collected across follow-up. Univariate and multivariable logistic regression models were used to evaluate factors associated with dysplasia and malignant transformation.
Results: Among 308 screened patients, 246 met inclusion criteria (173 women, 70.3%; mean age 63.2 ± 15.0 years) with a mean follow-up of 55.5 ± 37.0 months. At baseline, Candida spp. colonization was detected in 55 patients (22.4%) and was more frequent in red-type OLP than white-type lesions (33.3% vs. 17.0%; OR 2.44, 95% CI 1.32-4.53; p = 0.005). During follow-up, 33 patients (13.4%) developed fungal infection despite an initially negative swab. Epithelial dysplasia emerged in 42 patients (17.1%). In multivariable analysis, dysplasia was independently associated with increasing age (OR 1.06, 95% CI 1.03-1.10; p = 0.0001) and red-type OLP(OR 2.24, 95% CI 1.10-4.55; p = 0.026). Eight patients (3.25%) developed infiltrative OSCC after a mean interval of 28.3 months from OLP diagnosis (range 4-55).
Conclusions: In this long-term single-centre cohort, OLP frequently evolved through dysplasia during follow-up, and malignant transformation occurred in a minority of patients. Older age and red-type phenotype characterized patients more likely to develop dysplasia, while malignant transformation was more frequent in the case of previously documented dysplastic lesions, in keeping with the notion of dysplasia as a step along the carcinogenic pathway, older age, and diffuse lesions.
背景:口腔扁平苔藓(OLP)是一种具有恶性潜能的慢性免疫介导疾病。然而,其现实世界的临床过程仍然不完全表征。本研究旨在描述OLP在单一三级中心的自然临床-组织病理学轨迹,并确定与发育不良和恶性转化相关的因素。方法:我们在Fondazione Policlinico Universitario a . Gemelli IRCCS口腔医学部门进行了一项单中心回顾性队列研究,包括2007年至2024年间诊断为OLP的患者。在随访期间收集人口统计学、临床(红色与白色表型和病变分布)、微生物学(念珠菌)、治疗和组织病理学变量。单变量和多变量logistic回归模型用于评估与不典型增生和恶性转化相关的因素。结果:308例患者中,246例符合纳入标准(女性173例,70.3%,平均年龄63.2±15.0岁),平均随访时间55.5±37.0个月。基线时,55例患者(22.4%)检测到念珠菌定植,红色型OLP比白色型病变更常见(33.3%比17.0%;OR 2.44, 95% CI 1.32-4.53; p = 0.005)。在随访期间,33名患者(13.4%)出现真菌感染,尽管最初拭子呈阴性。42例(17.1%)出现上皮发育不良。在多变量分析中,发育不良与年龄增加(OR 1.06, 95% CI 1.03-1.10; p = 0.0001)和红色型OLP(OR 2.24, 95% CI 1.10-4.55; p = 0.026)独立相关。8例(3.25%)患者在OLP诊断后平均间隔28.3个月(范围4-55)发展为浸润性OSCC。结论:在这个长期的单中心队列中,OLP在随访期间经常因发育不良而发展,少数患者发生恶性转化。年龄较大和红型表型的患者更容易发生发育不良,而在先前记录的发育不良病变中,恶性转化更频繁,这与发育不良作为致癌途径的一个步骤、年龄较大和弥漫性病变的概念相一致。
{"title":"Long-Term Care of OLP Patients: A Retrospective Study From a Single Hospital Outpatient Clinic.","authors":"F Scilla, G Gioco, L Ferrero, R Castagnola, A Zafarone, L Cimino, M Tranfa, C Rupe, C Lajolo","doi":"10.1111/jop.70179","DOIUrl":"https://doi.org/10.1111/jop.70179","url":null,"abstract":"<p><strong>Background: </strong>Oral lichen planus (OLP) is a chronic immune-mediated disorder with malignant potential. However, its real-world clinical course remains incompletely characterized. This study aimed to describe the natural clinical-histopathological trajectory of OLP in a single tertiary centre and to identify factors associated with dysplasia and malignant transformation over time.</p><p><strong>Methods: </strong>We conducted a single-centre retrospective cohort study including patients diagnosed with OLP and followed between 2007 and 2024 at the Oral Medicine Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS. Demographic, clinical (red vs. white phenotype and lesion distribution), microbiological (Candida spp.), therapeutic, and histopathological variables were collected across follow-up. Univariate and multivariable logistic regression models were used to evaluate factors associated with dysplasia and malignant transformation.</p><p><strong>Results: </strong>Among 308 screened patients, 246 met inclusion criteria (173 women, 70.3%; mean age 63.2 ± 15.0 years) with a mean follow-up of 55.5 ± 37.0 months. At baseline, Candida spp. colonization was detected in 55 patients (22.4%) and was more frequent in red-type OLP than white-type lesions (33.3% vs. 17.0%; OR 2.44, 95% CI 1.32-4.53; p = 0.005). During follow-up, 33 patients (13.4%) developed fungal infection despite an initially negative swab. Epithelial dysplasia emerged in 42 patients (17.1%). In multivariable analysis, dysplasia was independently associated with increasing age (OR 1.06, 95% CI 1.03-1.10; p = 0.0001) and red-type OLP(OR 2.24, 95% CI 1.10-4.55; p = 0.026). Eight patients (3.25%) developed infiltrative OSCC after a mean interval of 28.3 months from OLP diagnosis (range 4-55).</p><p><strong>Conclusions: </strong>In this long-term single-centre cohort, OLP frequently evolved through dysplasia during follow-up, and malignant transformation occurred in a minority of patients. Older age and red-type phenotype characterized patients more likely to develop dysplasia, while malignant transformation was more frequent in the case of previously documented dysplastic lesions, in keeping with the notion of dysplasia as a step along the carcinogenic pathway, older age, and diffuse lesions.</p>","PeriodicalId":16588,"journal":{"name":"Journal of Oral Pathology & Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Aurora Kinase A (AURKA), a highly conserved and potent kinase, is frequently overexpressed in diverse cancers. However, its role in the malignant transformation (MT) of oral mucosa remains poorly understood. This study investigated the expression pattern of AURKA and evaluated the therapeutic potential of its inhibitor in oral leukoplakia (OLK), the most representative oral potentially malignant disorder.
Methods: Immunohistochemistry was performed on clinical samples (21 normal controls, 27 OLK, 23 MT of OLK) to examine AURKA expression and its correlation with clinicopathological characteristics. The inhibitory effect of targeting AURKA on tumor proliferation was verified in vitro using two oral squamous cell carcinoma (OSCC) cell lines. Additionally, the chemopreventive effect of the AURKA inhibitor Alisertib on MT was assessed using a 4-nitroquinoline oxide (4NQO)-induced mouse OLK model.
Results: AURKA expression levels positively correlated with the malignant progression of OLK. Significantly higher AURKA expression percentages were observed in non-homogeneous lesions (10.39% ± 4.28% vs. 3.53% ± 4.22% homogeneous, p < 0.001), lesions ≥ 2 cm2 (11.19% ± 4.55% vs. 4.69% ± 4.36% < 2 cm2, p < 0.01), and lesions with high-risk dysplasia (12.10% ± 4.04% vs. 4.59% ± 4.12% low-risk dysplasia, p < 0.001). Targeting AURKA significantly inhibited the proliferation of OSCC cells in vitro. Furthermore, Alisertib treatment effectively suppressed oral mucosa carcinogenesis in the 4NQO model.
Conclusion: Increased AURKA expression may represent an early molecular event in OLK carcinogenesis, and targeting AURKA with alisertib is a candidate for potential applications in the management of OLK.
背景:极光激酶A (AURKA)是一种高度保守和有效的激酶,在多种癌症中经常过表达。然而,其在口腔黏膜恶性转化(MT)中的作用仍然知之甚少。本研究研究了AURKA的表达模式,并评估了其抑制剂对口腔白斑(OLK)的治疗潜力,口腔白斑是最具代表性的口腔潜在恶性疾病。方法:采用免疫组化方法对临床标本(正常对照21例,OLK 27例,OLK 23 MT)检测AURKA表达及其与临床病理特征的相关性。利用两株口腔鳞状细胞癌(OSCC)细胞株,体外验证了靶向AURKA对肿瘤增殖的抑制作用。此外,利用4-硝基喹啉氧化物(4NQO)诱导的小鼠OLK模型,评估AURKA抑制剂Alisertib对MT的化学预防作用。结果:AURKA表达水平与OLK恶性进展呈正相关。在非均匀病变中,AURKA的表达率显著高于非均匀病变(10.39%±4.28% vs. 3.53%±4.22%,p 2(11.19%±4.55% vs. 4.69%±4.36%)2,p结论:AURKA表达升高可能代表OLK癌变的早期分子事件,alisertib靶向AURKA是OLK治疗的潜在应用候选。
{"title":"Inhibition of Aurora Kinase A Prevents Malignant Transformation in Oral Leukoplakia.","authors":"Fengying Yin, Mengjun Li, Yi Xu, Chuan Xin, Yining Li, Qianming Chen","doi":"10.1111/jop.70177","DOIUrl":"https://doi.org/10.1111/jop.70177","url":null,"abstract":"<p><strong>Background: </strong>Aurora Kinase A (AURKA), a highly conserved and potent kinase, is frequently overexpressed in diverse cancers. However, its role in the malignant transformation (MT) of oral mucosa remains poorly understood. This study investigated the expression pattern of AURKA and evaluated the therapeutic potential of its inhibitor in oral leukoplakia (OLK), the most representative oral potentially malignant disorder.</p><p><strong>Methods: </strong>Immunohistochemistry was performed on clinical samples (21 normal controls, 27 OLK, 23 MT of OLK) to examine AURKA expression and its correlation with clinicopathological characteristics. The inhibitory effect of targeting AURKA on tumor proliferation was verified in vitro using two oral squamous cell carcinoma (OSCC) cell lines. Additionally, the chemopreventive effect of the AURKA inhibitor Alisertib on MT was assessed using a 4-nitroquinoline oxide (4NQO)-induced mouse OLK model.</p><p><strong>Results: </strong>AURKA expression levels positively correlated with the malignant progression of OLK. Significantly higher AURKA expression percentages were observed in non-homogeneous lesions (10.39% ± 4.28% vs. 3.53% ± 4.22% homogeneous, p < 0.001), lesions ≥ 2 cm<sup>2</sup> (11.19% ± 4.55% vs. 4.69% ± 4.36% < 2 cm<sup>2</sup>, p < 0.01), and lesions with high-risk dysplasia (12.10% ± 4.04% vs. 4.59% ± 4.12% low-risk dysplasia, p < 0.001). Targeting AURKA significantly inhibited the proliferation of OSCC cells in vitro. Furthermore, Alisertib treatment effectively suppressed oral mucosa carcinogenesis in the 4NQO model.</p><p><strong>Conclusion: </strong>Increased AURKA expression may represent an early molecular event in OLK carcinogenesis, and targeting AURKA with alisertib is a candidate for potential applications in the management of OLK.</p>","PeriodicalId":16588,"journal":{"name":"Journal of Oral Pathology & Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148864733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}